GlassScriptPhysician profile
Joshua Bramson
NPI 1902937105
$3,760.33
in general payments reported to CMS, 2019-2025
42 companies · $488 in 2025
The $488 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $508 · 2021: $207 · 2022: $328 · 2023: $255 · 2024: $760 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.13 |
| Education | $101.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $467.33 | 2019-2025 | Opdualag, Krazati |
| Celgene Corporation | $269.15 | 2019-2022 | |
| Lilly USA, LLC | $259.69 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $247.81 | 2019-2023 | Padcev |
| Daiichi Sankyo INC. | $230.24 | 2020-2025 | Enhertu |
| Abbvie INC. | $229.24 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $196.18 | 2019-2021 | |
| Pfizer INC. | $183.25 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $165.06 | 2021-2025 | Ultomiris |
| Incyte Corporation | $158.94 | 2019-2023 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $139.25 | 2019-2020 | |
| Eisai INC. | $127.77 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $98.04 | 2019-2024 | Libtayo |
| Stemline Therapeutics INC. | $85.61 | 2019-2025 | Orserdu |
| Mirati Therapeutics, INC. | $76.75 | 2024 | Krazati |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Bramson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.